Russ Conroy

Preliminary findings from the MB-106 trial support the potential benefit of annamycin/cytarabine in patients with acute myeloid leukemia.

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Phase 2 findings support nana-val as a promising treatment option for those with EBV-positive peripheral T-cell lymphoma.

Results from the INSITE trial support the utility of pegulicianine fluorescence-guided surgery during breast cancer surgery.

Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.

TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.

Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Oncologic outcomes from a real-world analysis appear to be comparable with those observed in the sentinel lymph node biopsy arm of the SOUND trial.

Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

Real-world data may serve as a benchmark for future studies in elderly patients with acute myeloid leukemia.

Findings from SELECT-AML-1 support the potential benefit of tamibarotene in those with acute myeloid leukemia harboring RARA gene overexpression.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

The phase 1/2 WU-KONG1 findings support the breakthrough therapy designation for sunvozertinib for those with EGFR-mutated non–small cell lung cancer.

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Patients with muscle-invasive bladder cancer who remain molecular residual disease negative following cystectomy may be spared from adjuvant therapy.

Retrospective findings may establish a “framework” for improving the accessibility, timeliness, and appropriateness of surgical cancer care in disadvantaged areas.

Treatment with durvalumab raises no new safety signals among patients with limited-stage small cell lung cancer in the phase 3 ADRIATIC trial.

Further research may be needed to help determine the underlying mechanisms of polybrominated diphenyl ether exposure contributing to the risk of cancer-related mortality.

MK-1084 previously demonstrated manageable safety and preliminary activity in non–small cell lung cancer harboring KRAS G12C mutations as part of a phase 1 trial.

Enfortumab vedotin plus pembrolizumab appears to reduce the risk of disease progression or death vs chemotherapy in locally advanced or metastatic urothelial carcinoma.

Data from the phase 3 COMMANDS trial support the expanded European approval of frontline luspatercept for transfusion-dependent anemia in lower-risk myelodysplastic syndromes.

If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD.

Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.

Data from the phase 3 TROPION-Breast01 trial support the biologics license application for datopotamab deruxtecan in hormone receptor–positive, HER2-negative breast cancer.

The characteristics of rare earth ceramics may yield more consistent microwave energy penetration during the treatment of those with thyroid nodules.

Findings from the phase 2 SPEARHEAD-1 trial demonstrate how T-cell receptor therapy may effectively target solid tumors.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

Data from the phase 3 EV-302 trial support an application for enfortumab vedotin plus pembrolizumab as a treatment for patients with advanced bladder cancer in China.

Treatment with adagrasib in the phase 3 KRYSTAL-12 trial raised no new safety signals among patients with KRAS G12C–mutated non–small cell lung cancer.